195 related articles for article (PubMed ID: 30572795)
1. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1531-1533. PubMed ID: 30572795
[TBL] [Abstract][Full Text] [Related]
2. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
3. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Kaira K; Naruse I; Shimizu K; Asao T
J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
[TBL] [Abstract][Full Text] [Related]
4. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
Nitawaki T; Sakata Y; Kawamura K; Ichikado K
BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Ikeda S; Yoshioka H; Arita M; Sakai T; Sone N; Nishiyama A; Niwa T; Hotta M; Tanaka T; Ishida T
Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
Kashizaki F; Tanaka A; Sekido Y
J Med Case Rep; 2022 Aug; 16(1):316. PubMed ID: 35999557
[TBL] [Abstract][Full Text] [Related]
7. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
Masuda N; Ohe Y; Gemma A; Kusumoto M; Yamada I; Ishii T; Yamamoto N
Cancer Sci; 2019 Apr; 110(4):1401-1407. PubMed ID: 30776174
[TBL] [Abstract][Full Text] [Related]
9. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
10. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
12. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
14. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
15. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.
Huang JR; Chou CW; Chao HS
J Oncol Pharm Pract; 2021 Jul; 27(5):1311-1314. PubMed ID: 33054691
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
[TBL] [Abstract][Full Text] [Related]
17. Alectinib for ALK-positive non-small-cell lung cancer.
Rossi A
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
[TBL] [Abstract][Full Text] [Related]
18. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
[TBL] [Abstract][Full Text] [Related]
19. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
Ramachandran P; Morcus R; Tahir M; Onukogu I; Spinowitz B; Wang JC
J Med Case Rep; 2018 Oct; 12(1):303. PubMed ID: 30336782
[TBL] [Abstract][Full Text] [Related]
20. Alectinib for advanced
Ly AC; Olin JL; Smith MB
Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
